Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of <i>MYCN</i> Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction

28 Jul 2005

Abstract excerpt

PURPOSE: MYCN amplification (MNA) indicates a poor prognosis in neuroblastoma (NB) and is routinely assayed for therapy stratification. We aimed to develop a diagnostic tool to predict MYCN status using serum DNA, which, in cancer patients, predominantly originates from tumor-released DNA. PATIENTS AND METHODS: Using DNA-based real-time quantitative polymerase chain reaction, we simultaneously quantified MYCN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal and Paraganglionic Tumors
Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16051962
DOI: 10.1200/jco.2005.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of <i>MYCN</i> Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain ReactionPMID 16051962Read ↗

Detection of <i>MYCN</i> Amplification in Serum DNA Using Conventional Polymerase Chain ReactionSemantic proximity Read ↗

A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patientsSemantic proximity Read ↗

Influence of neuroblastoma stage on serum‐based detection of <i>MYCN</i> amplificationSemantic proximity Read ↗

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Plasma circulating cell-free MYCN gene: a noninvasive and prominent recurrence monitoring indicator of neuroblastomaSemantic proximity Read ↗

A systematic review of circulating-free MYCN amplification status as a noninvasive and prominent prognostic and recurrence monitoring indicator for neuroblastomaSemantic proximity Read ↗

Identification of patient subgroups with markedly disparate rates of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectSemantic proximity Read ↗

Circulating Methylated- DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified NeuroblastomaSemantic proximity Read ↗

MYCN protein stability is a better prognostic indicator in neuroblastomaSemantic proximity Read ↗

Heterogeneity of <i>MYCN</i> amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasisSemantic proximity Read ↗

The <i>MYCN</i> Enigma: Significance of <i>MYCN</i> Expression in NeuroblastomaSemantic proximity Read ↗

Relationship Between <i>MYCN</i> Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar SubtypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.